Royalty Pharma PLC reports results for the quarter ended June 30 - Earnings Summary

Royalty Pharma

06/08/2025 14:31

Royalty Pharma PLC RPRX.OQ reported quarterly adjusted earnings of $1.14​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 96 cents.  The mean expectation of five analysts for the quarter was for earnings of $1.09 per share. Wall Street expected results to range from $1.06  to $1.13 per share.

Revenue rose 19.6% to $727.00 million from a year ago; analysts expected $660.54 million.

Royalty Pharma PLC's reported EPS for the quarter was 5 cents​.

The company reported quarterly net income of $30 million.

Royalty Pharma PLC shares had risen by 5.2% this quarter and gained 48.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 8.9% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Royalty Pharma PLC is $42.00, about 9.7% above its last closing price of $37.91

This summary was machine generated from LSEG data August 6 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
1.09
1.14
Beat
Mar. 31 2025
1.59
0.65
Missed
Dec. 31 2024
1.05
1.15
Beat
Sep. 30 2024
0.93
1.01
Beat